

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application.

Claims 1-71 (canceled).

72. (currently amended): A compound comprising a chemically modified or unmodified double-stranded nucleic acid compound ~~that is~~ 19-23 ~~nucleobases~~ ~~nucleotides~~ in length, wherein a first strand of said compound has at least 19 contiguous ~~nucleobases~~ ~~nucleotides~~ of a ~~polynucleotide~~ nucleotide sequence selected from the group consisting of SEQ ID NOs:17, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 59, 61, 65, 67, 73, and 81, and wherein a second strand of said compound is 100% complementary to ~~the~~ said first strand.

73. (currently amended): The compound of Claim 72, which is blunt-ended or canonical.

74. (currently amended): The compound of Claim 72, comprising at least one chemical modification to a sugar, nucleobase, or internucleoside linkage.

75. (currently amended): The compound of Claim 74, wherein each chemical modification to ~~the~~ said sugar is a 2' modification.

76. (currently amended): The compound of Claim 75, wherein each 2' sugar modification is independently selected from the group consisting of ~~2'-O-methoxyethyl 2'-O-(2-methoxyethyl)~~ (2'-MOE), 2'-O-methyl, locked nucleic acid (LNA), and 2'-fluoro.

77. (currently amended): The compound of Claim 76, wherein each 2' sugar modification is a ~~2'-O-methoxyethyl 2'-O-(2-methoxyethyl)~~ (2'-MOE).

78. (currently amended): The compound of Claim 76, wherein each 2' sugar modification is a 2'-O-methyl.

79. (currently amended): The compound of Claim 76, wherein each 2' sugar modification is a 2'-fluoro.

80. (currently amended): The compound of Claim 76_z wherein each 2' modification of ~~the said~~ sugar results in a bicyclic sugar.

81. (currently amended): The compound of Claim 80_z wherein ~~the said~~ 2' bicyclic modification is a locked nucleic acid (LNA).

82. (currently amended): The compound of Claim 74_z wherein ~~the said~~ chemical modification to ~~the said~~ sugar is a 4' thio.

83. (currently amended): The compound of Claim 75_z comprising two or more chemically distinct 2' sugar modifications.

84. (currently amended): The compound of Claim 74_z comprising at least one internucleoside linkage modification.

85. (currently amended): The compound of Claim 84_z comprising mixed phosphorothioate and phosphodiester linkages.

86. (currently amended): The compound of Claim 85_z comprising alternating phosphorothioate and ~~phosphorodiester phosphodiester~~ internucleoside linkages.

87. (currently amended): The compound of Claim 76_z comprising at least one internucleoside linkage modification.

88. (currently amended): The compound of Claim 87_z comprising mixed phosphorothioate and phosphodiester linkages.

89. (currently amended): The compound of Claim 88_z comprising alternating phosphorothioate and ~~phosphorodiester phosphodiester~~ internucleoside linkages.

90. (currently amended): The compound of Claim 72_z comprising a conjugate.

91. (currently amended): The compound of Claim 72, where ~~the said~~ first strand consists of the nucleotide sequence shown in SEQ ID NO:81.

92. (currently amended): The compound of Claim 91, wherein ~~the said~~ compound is canonical.

93. (currently amended): A pharmaceutical composition, comprising ~~the said~~ compound of Claim 72 and a pharmaceutically acceptable carrier, ~~or~~ diluent, or excipient.

94. (currently amended): A method for treating a condition associated with survivin expression or overexpression, comprising administering to ~~an animal, particularly~~ a human, an effective amount of a said compound of Claim 72.

95. (currently amended): The method of Claim 94, wherein ~~the said~~ condition is cancer.

96. (currently amended): The method of Claim 95, wherein ~~the said~~ cancer is selected from the group consisting of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, lung cancer, bladder cancer, ovarian cancer, renal cancer, glioblastoma, pancreatic cancer, and non-Hodgkin's lymphoma.